Personalized mRNA Vaccine Spurs Lasting Immunity in TNBC
Abstract
In a small adjuvant trial of patients with early-stage triple-negative breast cancer, a personalized mRNA neoantigen vaccine induced robust, multitarget T-cell responses that persisted for years. Notably, the vaccine was administered on its own, without concurrent chemotherapy or checkpoint blockade, highlighting the treatment's stand-alone potential to drive durable antitumor immunity.
Fields of Study & Subjects
Immunotherapy and Immune Responses
Cancer Immunotherapy and Biomarkers
CAR-T cell therapy research
Publication details
- Journal / source
- Cancer Discovery
- Volume
- 16
- Issue
- 4
- Pages
- OF1–OF1
- Publication date
- 27 February 2026
- Language
- EN